Ophthalmic Consultants of Boston, Boston, Massachusetts.
Department of Ophthalmology, Center for Ophthalmic Bioinformatics, Cleveland Clinic, Cleveland, Ohio.
Retina. 2021 Jan 1;41(1):1-19. doi: 10.1097/IAE.0000000000003003.
To provide a concise overview for ophthalmologists and practicing retina specialists of available clinical evidence of manipulating the angiopoietin/tyrosine kinase with immunoglobulin-like and endothelial growth factor-like domains (Tie) pathway and its potential as a therapeutic target in retinal vascular diseases.
A literature search for articles on the angiopoietin/Tie pathway and molecules targeting this pathway that have reached Phase 2 or 3 trials was undertaken on PubMed, Association for Research in Vision and Ophthalmology meeting abstracts (2014-2019), and ClinicalTrials.gov databases. Additional information on identified pipeline drugs was obtained from publicly available information on company websites.
The PubMed and Association for Research in Vision and Ophthalmology meeting abstract search yielded 462 results, of which 251 publications not relevant to the scope of the review were excluded. Of the 141 trials related to the angiopoietin/Tie pathway on ClinicalTrials.gov, seven trials focusing on diseases covered in this review were selected. Vision/anatomic outcomes from key clinical trials on molecules targeting the angiopoietin/Tie pathway in patients with retinal vascular diseases are discussed.
Initial clinical evidence suggests a potential benefit of targeting the angiopoietin/Tie pathway and vascular endothelial growth factor-A over anti-vascular endothelial growth factor-A monotherapy alone, in part due to of the synergistic nature of the pathways.
为眼科医生和从事视网膜专业的医生提供有关血管生成素/含免疫球蛋白样和表皮生长因子样结构域酪氨酸激酶（Tie）通路的现有临床证据的简要概述，并介绍其作为视网膜血管疾病治疗靶点的潜力。
在 PubMed、美国眼科学会（ARVO）会议摘要（2014-2019 年）和 ClinicalTrials.gov 数据库中，对血管生成素/Tie 通路和靶向该通路的分子的相关文献进行了检索，这些文献已进入 2 期或 3 期临床试验。从公司网站上公开的信息中获取了已确定的在研药物的更多信息。
PubMed 和 ARVO 会议摘要搜索共产生了 462 项结果，其中 251 项与综述范围不相关的出版物被排除。在 ClinicalTrials.gov 上与血管生成素/Tie 通路相关的 141 项试验中，选择了 7 项针对本综述涵盖疾病的试验。讨论了靶向血管生成素/Tie 通路的分子在视网膜血管疾病患者中的关键临床试验的视力/解剖学结果。
初步临床证据表明，靶向血管生成素/Tie 通路和血管内皮生长因子-A 可能优于单独抗血管内皮生长因子-A 治疗，部分原因是这些通路具有协同作用。
